![]() | Up a level |
Journal Article
Kim, Dong-Wan, Mehra, Ranee, Tan, Daniel S. W., Felip, Enriqueta, Chow, Laura Q. M., Camidge, D. Ross, Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin, Liu, Geoffrey ORCID: 0000-0002-2603-7296, Santoro, Armando
ORCID: 0000-0003-1709-9492, Sutradhar, Santosh, Li, Siyu, Szczudlo, Tomasz, Yovine, Alejandro and Shaw, Alice T.
(2016).
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Lancet Oncol., 17 (4).
S. 452 - 464.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1474-5488
Kim, Dong-Wan, Tan, Daniel Shao-Weng, Aix, Santiago Ponce, Sequist, Lecia V., Smit, Egbert F., Hida, Toyoaki, Yang, James Chih-Hsin, Felip, Enriqueta, Seto, Takashi, Grohe, Christian, Wolf, Juergen, Ko, Jinnie, Diallo, Mariama, Pultar, Philippe, Giovannini, Monica and Kim, Sang-We (2018). Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC). J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Tan, Daniel S-W, Leighl, Natasha B., Riely, Gregory J., Yang, James C-H, Sequist, Lecia, V, Wolf, Juergen, Seto, Takashi, Felip, Enriqueta, Aix, Santiago P., Jonnaert, Maud, Pan, Chun, Tan, Eugene Y., Ko, Jinnie, Moody, Susan E. and Kim, Dong-Wan (2020). Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. Lancet Resp. Med., 8 (6). S. 561 - 573. OXFORD: ELSEVIER SCI LTD. ISSN 2213-2600
Tan, Daniel Shao-Weng, Leighl, Natasha B., Yang, James Chih-Hsin, Riely, Gregory J., Sequist, Lecia, V, Toyozawa, Ryo, Wolf, Juergen, Felip, Enriqueta, Kim, Sang-We, Aix, Santiago Ponce, Smit, Egbert F., Hida, Toyoaki, Grohe, Christian, Ghebremariam, Samson, O'Sullivan-Djentuh, Leslie, Belli, Riccardo, Giovannini, Monica and Kim, Dong-Wan (2020). Nazartinib (EGF816) in patients with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results. J. Clin. Oncol., 38 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Tan, Daniel Shao-Weng, Yang, James Chih-Hsin, Leighl, Natasha B., Riely, Gregory J., Sequist, Lecia V., Felip, Enriqueta, Seto, Takashi, Wolf, Juergen, Moody, Susan Elizabeth, Adams, Kenneth, Schmitz, Shu-Fang Hsu, Tan, Eugene Y. and Kim, Dong-Wan (2016). Updated results of a phase 1 study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755